Medtronic has received FDA clearance for its Stealth AXiS surgical system, a navigation platform designed to enhance precision during spine procedures. The system incorporates LiveAlign segmental tracking technology, which enables surgeons to monitor anatomical movement in real-time throughout the operation, potentially reducing the frequency of intraoperative imaging and associated radiation exposure.
The clearance represents an expansion of Medtronic's surgical navigation portfolio in the spine care segment. LiveAlign's real-time tracking capability addresses a longstanding challenge in spinal surgery by providing continuous visualization of vertebral alignment and movement, allowing surgeons to make more informed decisions during complex procedures without relying on repeated imaging intervals.
The technology is positioned to streamline surgical workflows while maintaining safety and accuracy standards. Industry analysts have maintained a Buy rating on Medtronic stock with a $110.29 price target, reflecting confidence in the company's continued innovation within its surgical technologies division.